---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-021706"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:37:10.702454+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Glucotrack submits IDE to FDA for US clinical study of implantable CBGM

## Summary
- Glucotrack submitted an IDE application to the FDA to initiate a US clinical study of its fully implantable continuous blood glucose monitoring (CBGM) system.
- CBGM is designed for 3-year sensor longevity, blood-based accuracy, and no on-body wearable component.
- Company plans to proceed with US clinical study following FDA review and approval of the IDE.
- IDE submission follows years of preclinical evaluation and iterative engineering; data support advancing to clinical evaluation.
- CEO Paul Goode stated the submission reflects progress toward offering a discreet, accurate CGM option for diabetes patients.

## SEC filing metadata
- accession: 0001493152-26-021706
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000149315226021706/0001493152-26-021706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000149315226021706/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-021706
- JSON: https://secwatch.observer/filing/0001493152-26-021706.json
- Plain text: https://secwatch.observer/filing/0001493152-26-021706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.